Companion Diagnostics โ Integration of Biomarker Tests with Therapeutic Agent Labels
Why It Matters
In cancer and rare disease treatment, biomarker testing is increasingly linked to drug selection. However, not all tests that are statistically associated with treatment response qualify as companion diagnostics (CDx). A CDx is a diagnostic device whose specific intended use and performance have been regulatory-evaluated to provide essential information for the safe and effective use of a particular therapeutic product.
Assays with the same gene name cannot be used interchange simply because they target the same gene. Differences in specimen type, platform, variant coverage, scoring criteria, and cutoff values can result in a discrepancy between the population validated in clinical trials and the population tested in practice.
Differences Between Biomarkers and CDx
Prognostic biomarkers may be associated with disease progression independent of treatment, whereas predictive biomarkers may be associated with relative differences in the efficacy of specific treatments. In addition to these biological relationships, a CDx carries a regulatory role linked to the labeling of a specific therapeutic product.
Even if an assay is clinically useful, it may occupy other positions, such as complementary diagnostic, if it is not essential for drug use or follows a separate regulatory pathway. Terminology should be verified according to national and document-specific contexts.
Co-developed Elements
Clinical trials of therapeutic agents can simultaneously design the assay, specimen handling, analytical cutoff, and clinical endpoint required to define a biomarker-positive population. This involves evaluating not only the sensitivity and specificity of the assay but also determining which patients are classified as treatment targets based on the results.
Tissue biopsies, blood, and cytology specimens differ in analyte quantity and preprocessing requirements. Validation agreements include IHC staining and scoring, PCR targets, variant inclusion criteria for NGS panels, and bioinformatics pipelines.
How to Interpret Labels
Device labels specify intended use, target specimen, testing method, cutoff values, performance characteristics, and limitations. Therapeutic labels may include indications, required biomarkers, and information on approved tests. In practice, the two most recent documents from the same jurisdiction should be reviewed together.
Assay or drug labels may change after approval, and multiple companion diagnostics (CDx) may be approved for the same therapy. Do not assume that assays described in older publications remain currently approved.
Small Example
Suppose a therapy-related gene alteration is identified in research-use-only NGS. Even if the result is biologically interesting, it must be confirmed whether the variant class, specimen type, and validated assay range required by the drug label are met. Whether results from other platforms can be used depends on bridging evidence and regional regulations.
IHC scores cannot be directly interpreted numerically if the antibody clone, scoring algorithm, or tumor-type-specific cutoffs differ.
From Analytical Validity to Clinical Utility
Analytical validity asks whether an assay accurately and reproducibly measures its target; clinical validity asks about the relationship between a biomarker and clinical outcomes; and clinical utility asks whether test use aids decision-making and patient outcomes. CDx development connects these layers, but success in one layer does not automatically guarantee success in another.
Common Misconceptions
- A predictive biomarker paper does not necessarily imply an approved companion diagnostic (CDx).
- Assays targeting the same gene are not automatically interchangeable.
- The regulatory status of laboratory-developed tests versus approved CDx varies by jurisdiction.
- Driver mutations do not automatically qualify as CDx biomarkers or actionable findings.
- A negative result does not guarantee the absence of alterations outside the assayโs detection range.
Interpretive Criteria
The status of CDx and the therapeutic indication vary by region and time point. It is essential to consult the most current device and drug labeling as well as professional guidelines; this article does not propose treatment choices for individual patients.
Reading in Context
The distinction between drivers and actionability is linked to the concepts of Cancer driver mutation evidence, immune therapy biomarkers as Immune checkpoint inhibitors, and assay-specific detection ranges as WGSยทWESยทpanel selection.